Self-Immolating Linker Conjugates Reduce Systemic Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chemotherapy often results in systemic adverse effects due to the non-selective action of active agents on both target and non-target cells, as the linker moiety in conjugates can undergo premature cleavage, releasing the active agent into the bloodstream.
Innovation Solution
A conjugate structure T-(L-(D-Z))n is developed, where T is a targeting moiety, D-Z is a modified active agent with a cell membrane-impermeabilizing moiety Z, and L is a linker moiety susceptible to cleavage inside the target cell, reducing premature release and systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a linker moiety is used to conjugate the active agent to the targeting moiety, then the active agent can be delivered to the target cell, but the linker moiety undergoes premature cleavage in blood plasma, resulting in systemic toxicity
Solution Approach 1:
The patent changes the chemical parameters of the linker moiety by incorporating a self-immolating spacer (such as p-aminobenzyl carbamate) that undergoes controlled decomposition after enzymatic cleavage. This parameter change ensures the linker remains stable in blood plasma (pH 7.4) while enabling controlled release at the target site through sequential chemical reactions triggered by lysosomal enzymes.
Solution Approach 2:
The patent introduces a self-immolating spacer as an intermediary component between the linker and the active agent. This intermediary serves as a protective barrier that prevents premature release of the active agent in circulation, while simultaneously providing a controlled mechanism for release at the target cell through enzymatic triggering followed by spontaneous decomposition of the spacer.
2Object-affected harmful factors
If the active agent is made latent through conjugation, then systemic toxicity is reduced, but the active agent must be released inside the target cell to be effective
Solution Approach 1:
The patent applies preliminary action by pre-configuring the linker moiety with a self-immolating spacer designed to respond to specific intracellular conditions (lysosomal enzymes and acidic pH). The spacer is pre-programmed to undergo sequential reactions: first enzymatic cleavage of the peptide bond, then spontaneous decomposition releasing the active agent. This preliminary design ensures reliable release at the target site without requiring additional activation steps.
Solution Approach 2:
The patent converts the potentially harmful instability of the linker into a beneficial controlled release mechanism. The self-immolating spacer is designed to be unstable under specific intracellular conditions (acidic pH and presence of lysosomal enzymes), but this instability is precisely what enables the controlled release of the active agent at the target site. The apparent weakness (instability) becomes the mechanism for precise delivery.
3Measurement precision
If a pH-sensitive linker is used to exploit the pH difference between blood plasma and lysosome, then selective cleavage inside the target cell is achieved, but premature cleavage in blood plasma still occurs at about 1% of the lysosomal rate
Solution Approach 1:
The patent segments the cleavage process into two distinct stages: first, enzymatic cleavage of the peptide bond by lysosomal enzymes, and second, spontaneous decomposition of the self-immolating spacer. This segmentation ensures that the active agent is not released until both conditions are met (enzymatic recognition and acidic pH), dramatically reducing premature release compared to using only a pH-sensitive linker.
Solution Approach 2:
The patent applies preliminary action by designing the self-immolating spacer to remain intact during circulation and only become active after enzymatic triggering. The spacer is pre-configured with a latent decomposition mechanism that is activated only after the peptide bond is cleaved by lysosomal enzymes, ensuring that the active agent is released only at the target site and not during circulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate design minimizes premature release of the active agent, thereby reducing systemic toxicity and enhancing the selectivity of the therapeutic effect on target cells, thereby reducing adverse systemic effects.
Implementation Method 1
The lysosomal environment is more acidic (typically about pH 5) than blood plasma (typically about pH 7.3), so that a linker moiety that is pH sensitive can be selectively cleaved inside a target cell
Implementation Method 2
A lysosome contains acid hydrolases, which are peptidases active at acidic pH's. A peptidic linker moiety that is a specific substrate for the acid hydrolases will be cleaved preferentially inside a lysosome
Data Source
AI summary
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.